Gathering in Yuzhang for a Grand Event—Healrna Show cases Innovative mRNA Vaccine Solutions for Veterinary Use at the 11th China Veterinary Drug Exposition

On June 18–19, 2025, the 11th China Veterinary Drug Exposition, hosted by the China Veterinary Drug Association, was successfully held at the Nanchang Greenland International Expo Center. Under the theme "Pioneering Transformation, Integrated Innovation, and Intelligence for the Future," the event attracted over 350 exhibitors. Healrna made a notable appearance, presenting its cutting-edge mRNA vaccine solutions for veterinary applications.

At the exposition, Healrna showcased multiple globally leading innovations in veterinary mRNA vaccines, including breakthrough products such as its self-developed mRNA vaccines for Porcine Epidemic Diarrhea (PED) and Feline Infectious Peritonitis (FIP), which drew significant industry attention. The exhibition floor was bustling with activity, and Healrna’s booth remained a hotspot throughout the event, attracting a continuous stream of professional visitors. Numerous industry experts and representatives from peer companies engaged in in-depth discussions, sparking lively exchanges on the innovative applications of mRNA technology in veterinary medicine and jointly promoting technological advancement and healthy development within the industry. This series of proprietary core technologies fully demonstrated Healrna’s formidable strength in scientific and technological innovation within the veterinary biologics sector.

The 2nd Key Technologies Symposium on Veterinary Nucleic Acid Drugs

On June 19, during the exhibition, the 2nd Key Technologies Symposium on Veterinary Nucleic Acid Drugs was successfully held. The event was hosted by the China Veterinary Drug Association, co-organized by the National Veterinary Drug Industry Technology Innovation Alliance and Ringpu (Tianjin) Bio-Pharmacy Co., Ltd., undertaken by the Nucleic Acid Drugs Branch of the China Veterinary Drug Association, and supported by companies such as Healrna.

At the opening ceremony, Cai Xuepeng, Chairman of the National Veterinary Drug Industry Technology Innovation Alliance, delivered the opening remarks. Subsequently, Yin Chunsheng, a researcher from the China Institute of Veterinary Drug Control, presented a special report on "Registration Requirements for Veterinary Vaccines." He systematically interpreted relevant regulatory policies, technical standards, and approval procedures for vaccine registration, while providing professional recommendations and guidance specifically for nucleic acid vaccine registration.

Professor Zhao Lixiang, co-founder of Healrna and faculty member of Soochow University, delivered a keynote speech titled "Development and Breakthroughs in Key Technologies of Veterinary mRNA Vaccines." His presentation comprehensively reviewed the evolution of mRNA vaccines, analyzed critical technological aspects and patent strategies in depth, and elaborated on mRNA vaccine design characterization and expression detection methods. Notably, Professor Zhao highlighted the R&D achievements of PEDV and PDCoV mRNA vaccines utilizing the company’s self-developed LNP delivery system. Comparative experimental data against traditional vaccines demonstrated that Healrna’s mRNA vaccines exhibit significant advantages in both neutralizing antibody induction and safety.

This symposium provided a high-level platform for technical exchange within the industry. Experts engaged in in-depth discussions on key technological challenges in veterinary nucleic acid drug development, offering valuable insights to drive innovation in China’s veterinary biologics sector.

Through this exhibition, Healrna not only deepened technical exchanges and cooperation with industry partners but also expanded innovative thinking and reinforced its development philosophy of "Technology Safeguarding Life." We sincerely appreciate all the friends who visited and supported Healrna. Looking ahead, Healrna will embrace a more open approach, leverage cutting-edge technologies, and deliver superior products to jointly explore new frontiers in life and health protection with you. Innovation never stops, and safeguarding never ceases—Healrna looks forward to creating more brilliance with you!

#About Healrna #

Healrna is a high-tech enterprise dedicated to the comprehensive industrialization of nucleic acid drugs. The company's business spans mRNA drug R&D and production, clinical trial design, data analysis, and other fields, with a focus on developing mRNA-based solutions for infectious disease vaccines, cancer vaccines, cell therapy, protein replacement, and more.